MTI外刊阅读精选中国誓言加快削减抗癌药价格.docx
MTI外刊阅读精选中国誓言加快削减抗癌药价格China vows price cuts to cancer drugsChina has vowed to speed up cuts to the cost of cancer drugs in a move that threatens to dent revenues in the country for multinationals such as Eli Lilly, Roche and Novartis.中国誓言要加快削减抗癌药物的价格,此举可能冲击礼来(Eli Lilly)、罗氏(Roche)和诺华(Novartis)等跨国公司的在华营收。Officials will “accelerate price cuts” for cancer treatments, the Communist party-run Peoples Daily reported over the weekend. The news comes after China slashed the cost of dozens of overseas drugs by as much as 70 per cent after price negotiations last year.据中共机关报人民日报(Peoples Daily)上周末报道,官员们将加速癌症治疗药物的降价。此前,中国在去年谈判价格后,已将许多种海外药品的价格削减至多 70%。The report coincided with the release of a box office-topping film about patients forced to smuggle cheap generics, adding to pressure on drugmakers in the country.这一报道发表之际,适逢一部讲述患者被迫走私廉价仿制药的卖座电影上映,加大了在华经营的制药商所受到的压力。China is the worlds second-largest medical pharmaceuticals market after the US by sales, which were worth $123bn last year according to London-based L.E.K. Consulting. It is a key growth market for drugs to treat cancer, with more than 4m new cases diagnosed each year.据总部位于伦敦的艾意凯咨询公司(LEK Consulting)介绍,中国是销售额仅次于美国的全球第二大医药市场,去年价值1230亿美元。中国是癌症治疗药物的关键增长市场,每年有逾 400万新病例被确诊。Drugs already covered by state-insurance could have their prices cut by 10 per cent, with reductions of up to 50 per cent for other medications as a condition of them being added to the state insurance scheme, according to Zhao Heng of Latitude Health, a consultancy.据咨询公司 Latitude Health的 Zhao Heng称,国家医保目录内的药物价格可能降低 10%,其他药物的价格可能降低至多 50%,作为其被纳入国家医保目录的先决条件。“Almost all cancer drugs made by multinationals may see price cuts,” he added.“跨国公司生产的几乎所有抗癌药都可能会降价。”他补充道。US drugmaker Eli Lillys Pemetrexed, along with Letrozole from Switzerlands Novartis and Roches Capecitabine, are among the top 20 selling anti-cancer drugs in China, making them likely targets for the cuts.美国制药商礼来的培美曲塞(Pemetrexed),以及瑞士诺华的来曲唑(Letrozole)和罗氏的卡培他滨(Capecitabine),都在中国销售额最高的 20种抗癌药物之列,这使它们成为很有可能的降价目标。Several multinational pharma companies have been invited for talks with government officials over prices this week, according to people familiar with the matter. “It will be an intense negotiation,” said an executive at one European drugmaker.据知情人士透露,多家跨国制药公司本周接到了与政府官员谈判价格的邀请。“这将是一场激烈的谈判。”某家欧洲制药商的一位高管表示。The Peoples Daily cited an official at Chinas new state medical insurance administration, which was created in March to increase the state insurance funds influence over health policy.人民日报援引了今年 3月刚成立的中国国家医疗保障局一名官员的话。该局旨在加大国家医保基金对卫生政策的影响力。The report came shortly after the release of Chinese comedy drama Dying to Survive, based on the true story of a Chinese businessman who illegally imported generic cancer drugs from India to sell to impoverished patients, before being detained for smuggling.中国喜剧片我不是药神就在这篇报道出炉前不久上映。影片取材于一个真实故事,讲述一个中国商人从印度非法进口仿制药出售给贫困患者,结果因涉嫌走私而被拘留。The movie, which has been likened to the 2013 film Dallas Buyers Club, has topped Chinas box office since its release last week, earning $200m in four days. It is rare for Chinese censors to approve films presenting lawbreaking in a positive light, suggesting that officials intended its release to send a message to the industry.已被比作 2013年美国剧情片达拉斯买家俱乐部(Dallas Buyers Club)的我不是药神,自上周发行以来就登顶中国内地票房榜,四天收入 2亿美元。中国审查机构极少批准从正面视角展示违法行为的电影,似乎表明官方希望其上映向业界传递一个信息。The films plot revolves around high prices charged by a foreign drugmaker whose Chinese name bears a close resemblance to that of Novartis, and a medicine whose name sounds similar to its cancer treatment Gleevec.该片的情节围绕某家外国制药公司收取的高价,该公司的中文名称听上去有点像“诺华”,而且药名听上去与诺华的抗癌药格列卫(Gleevec)相似。Officials have encouraged companies to cut prices by threatening a switch to cheaper, local generics in state hospitals, where most medicines are sold in China. But in a positive move for multinationals, they have also accelerated approvals for innovative drugs.为鼓励企业降低药价,官员们威胁要在国营医院(在华销售药物的主要渠道)改用更便宜的本地仿制药。但对跨国公司来说,积极的一面是官方也加快了对创新药物的审批。Shares in Chinese generic drugmakers such as Anhui Sunhere Pharma rose as much as 10 per cent yesterday, as the film helped increase awareness of the efficacy of generic drugs, according to analysts at Sina Finance.新浪财经(Sina Finance)的分析师们表示,安徽山河药用辅料(Anhui Sunhere Pharma)等中国仿制药企业的股价昨日上涨至多 10%,因为我不是药神帮助提高了人们对仿制药疗效的认识。In a silver-lining for drugmakers, price cuts could boost sales. For example, Roche cut the price of chemotherapy drug Avastin in China by nearly 70 per cent last year, but achieved about a 25 per cent rise in revenues for the medicine after its addition to state insurance increased sales, according to UBS.对于制药商而言,“乌云的金边”在于降价有望提振销售。例如,据瑞银(UBS)介绍,罗氏去年将化疗药物阿瓦斯汀(Avastin)的中国销售价格降低近 70%,但在进入国家医保药品目录后,该药的营收实现了约 25%增长。